<DOC>
	<DOCNO>NCT02601976</DOCNO>
	<brief_summary>Hepatitis C global problem , prevalent develop well develop country . New treatment regimens use PegInterferon combination ribavirin lead improved sustained viral response rate genotypes . A single arm , open label , multicentre trial conduct evaluate response rate safety PegInterferon alfa-2a ( Unipeg® ) plus ribavirin ( Ribazole® ) treatment patient chronic hepatitis C infection . RVR 4 week , ETR 24 week genotype 3 48 week genotype 1 patient SVR determine 24 week completion treatment . Quality life baseline follow-up visit determine use SF-36 .</brief_summary>
	<brief_title>Evaluation Unipeg® Response Ongoing Safety Pakistani Population</brief_title>
	<detailed_description>A multicenter , phase IV , open label , single arm study conduct . Total 110 patient screened recruitment . Out 67 subject meet inclusion criterion , 3 fail give inform consent exclude . The final sample size study 64 patient . The duration study August 2010 September 2013 . Peginterferon alfa-2a 180µg 20kDa ( Unipeg® ) solution injection administer single dose sub-cutaneous weekly 24 week patient genotype 3 48 week patient genotype 1 site recruitment . Ribavirin ( Ribazole ) orally give divide daily dose accord body weight-based dosing recommendation ( &lt; 75kg = 1000 mg ≥ 75 kg = 1200 mg ) . Quality life relate Physical Component Score ( PCS ) &amp; Mental Component Score ( MCS ) measure Health-Related Quality Life ( HRQOL ) Questionnaire ( SF-36 ) . The SF-36 questionnaire complete patient evaluation treatment , 4 week , end treatment 24 week completion treatment .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . Written Informed consent 2 . Treatment naïve patient 3 . Serological evidence hepatitis C infection antiHCV antibody test 4 . HCV positive PCR 5 . Genotype 1,2 3 6 . BMI 2028 7 . Participants resident city /she enrol respective centre 8 . No evidence liver cirrhosis 9 . No significant hepatic systemic disease 10 . No evidence hepatic encephalopathy 11 . Normal thyroid function ( By test TSH ) 12 . Adequate bone marrow , liver renal function test Hematology : ANC≥1,000/mm3 , Platelet count ≥100,000 mm3 , Hemoglobin≥11.0g/dl female ≥ 12.0 g/dl male Blood Chemistry : Total Bilirubin≤2.0mg/dl , AST ALT &lt; 3 time normal Creatinine Clearance &gt; 50 ml/min Proteinuria : ≤ 0.5 g per 24h . Prothrombin Time partialthromboplastin time ≤1.5 time upper limit normal range . 1 . Unable give consent 2 . Prior treatment Hepatitis C 3 . Coinfection HBV HCV 4 . Obesity 5 . Iron overload 6 . Other Genotypes e.g . 4 , 5 , 6 subtypes 7 . Pregnant lactate woman 8 . History medical condition associate chronic liver disease CHC ( e.g . hemochromatosis , autoimmune hepatitis , metabolic liver disease , alcoholic liver disease , toxin exposure ) 9 . Uncontrolled Hypertension 10 . Uncontrolled Diabetes 11 . Severe Depression 12 . Clinically significant cardiovascular disease 13 . Symptomatic peripheral vascular disease 14 . Oral parenteral anticoagulant anti platelet agent 15 . History systemic antiviral therapy least three month prior first dose study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>PegInterferon alpha-2a</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>Sustained Virological Response</keyword>
	<keyword>End Treatment Response</keyword>
	<keyword>Unipeg</keyword>
	<keyword>Ribazole</keyword>
</DOC>